|
|
|
|
| LEADER |
11212nam a22004693i 4500 |
| 001 |
EBC6877842 |
| 003 |
MiAaPQ |
| 005 |
20231204023220.0 |
| 006 |
m o d | |
| 007 |
cr cnu|||||||| |
| 008 |
231204s2022 xx o ||||0 eng d |
| 020 |
|
|
|a 9783030860769
|q (electronic bk.)
|
| 020 |
|
|
|z 9783030860752
|
| 035 |
|
|
|a (MiAaPQ)EBC6877842
|
| 035 |
|
|
|a (Au-PeEL)EBL6877842
|
| 035 |
|
|
|a (OCoLC)1295275583
|
| 040 |
|
|
|a MiAaPQ
|b eng
|e rda
|e pn
|c MiAaPQ
|d MiAaPQ
|
| 050 |
|
4 |
|a RC1-1245
|
| 100 |
1 |
|
|a von Eckardstein, Arnold.
|
| 245 |
1 |
0 |
|a Prevention and Treatment of Atherosclerosis :
|b Improving State-Of-the-Art Management and Search for Novel Targets.
|
| 250 |
|
|
|a 1st ed.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing AG,
|c 2022.
|
| 264 |
|
4 |
|c ©2022.
|
| 300 |
|
|
|a 1 online resource (537 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Handbook of Experimental Pharmacology Series ;
|v v.270
|
| 505 |
0 |
|
|a Intro -- Preface -- Acknowledgement -- Contents -- Part I: Improving the Treatment of Established Targets -- Diet, Lifestyle, Smoking -- 1 Diet -- 1.1 Dietary Fat (Table 1) -- 1.1.1 Effects on CVD Risk Factors -- 1.1.2 Effects on CVD Events -- 1.2 Dietary Carbohydrates (Table 1) -- 1.2.1 Effects on CVD Risk Factors -- 1.2.2 Effects on CVD Events -- 1.3 Salt (Table 1) -- 1.3.1 Effects on CVD Risk Factors -- 1.3.2 Effects on CVD Events -- 2 Physical Activity -- 3 Smoking -- References -- Blood Pressure-Lowering Therapy -- 1 Introduction -- 2 Non-pharmacological Therapy -- 2.1 Salt Restriction -- 2.2 Reduce Alcohol Intake -- 2.3 Weight Loss and Avoidance of Overweight and Obesity -- 2.4 Regular Physical Activity -- 3 Pharmacological Therapy for the Treatment of Arterial Hypertension -- 3.1 Who Should Be Treated with Pharmacological Therapy? -- 3.2 Choice of Initial Antihypertensive Agents -- 3.3 Combination Therapy -- 3.4 Direct Effects of Antihypertensive Drugs on Atherosclerosis -- 3.4.1 ARBs and ACE Inhibitors -- 3.4.2 Diuretics -- 3.4.3 Calcium Antagonists -- 3.4.4 Beta-Blockers -- 3.4.5 Mineralocorticoid Receptor Antagonists -- 4 Perspectives of Future Antihypertensive Therapy -- 4.1 Unresolved Medical Needs -- 4.2 New Drug Developments -- 4.3 Device Therapy -- 5 Conclusion -- References -- Glycaemic Control in Diabetes -- 1 Cardiovascular Risk in Diabetes -- 2 Microvascular End-Organ Damage and Cardiovascular Risk -- 3 Role of Hyperglycaemia for Micro- and Macro-vascular Complications -- 4 Role of Hyperglycaemia in Reducing Vascular Risks in Type 1 Diabetes -- 5 Efficacy Trials of Glucose Lowering in Type 2 Diabetes -- 6 Cardiovascular Safety Studies in Type 2 Diabetes -- 7 GLP-1 Receptor Agonists (GLP-1-RA) -- 8 SGLT (Sodium Glucose Transporter) 2 Inhibitors -- 9 Mechanisms of Action for Cardio-Renal Protection Through SGLT-2 Inhibition.
|
| 505 |
8 |
|
|a 10 Change in Guidelines and Clinical Recommendations -- 11 Perspectives: Fat Partitioning as a New Target of Diabetes Drugs -- References -- LDL-Cholesterol-Lowering Therapy -- 1 Introduction -- 2 Statins in the Prevention of Cardiovascular Disease -- 3 Non-statin Cholesterol-Lowering Drugs -- 3.1 Ezetimibe -- 3.2 PCSK9 Inhibitors -- 3.2.1 Evolocumab -- 3.2.2 Alirocumab -- 3.3 Lomitapide -- 3.4 Mipomersen -- 4 Cholesterol-Lowering Drugs Under Clinical Development -- 4.1 Inclisiran -- 4.2 Bempedoic Acid -- 5 The Future of Cholesterol Lowering -- 5.1 ANGPTL3-LRx -- 6 Conclusions -- References -- Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis -- 1 Atherogenesis and the Role of Blood Coagulation Components -- 1.1 Blood Coagulation: Impact on Vascular Endothelial Cells -- 1.2 Platelets and Extracellular Vesicles -- 1.3 Antiplatelet Agents and Atherosclerosis -- 1.4 Coagulation Proteases -- 2 From Atherosclerosis to Atherothrombosis -- 3 Antithrombotic Therapy: Clinical Principles and Applications -- 3.1 Single Antiplatelet Agents: Mode of Action and Side Effects -- 3.2 Primary Prevention in the Population -- Selecting the Right Subject? -- 3.3 Primary Prevention in Subjects with Atherosclerosis -- 3.4 Secondary Prevention of Atherothrombosis in Patients with Arterial Vascular Disease -- 4 The Effects of Antithrombotic Therapy on the Vessel Wall and Atherogenesis: Clinical Relevance? -- 5 Novel Antiplatelet and Anticoagulant Targets -- References -- Part II: Novel Drug Developments Addressing Predefined Targets -- Metabolism of Triglyceride-Rich Lipoproteins -- 1 Introduction -- 2 Hepatic Formation and Secretion of VLDL -- 3 Regulators of Hepatic VLDL Secretion -- 4 Synthesis and Secretion of Chylomicrons from the Intestine -- 5 Disorders of the Synthesis of TRLs -- 6 Metabolism of Triglyceride-Rich Lipoproteins.
|
| 505 |
8 |
|
|a 7 Deciphering the Pathogenesis of Hypertriglyceridemia -- 8 Regulation of Hydrolysis of TRLs and the LPL Pathway -- 9 Role of Triglyceride-Rich Lipoproteins in Atherogenesis -- 10 Therapies to Reduce Triglyceride-Rich Lipoproteins -- 11 Development of Novel Interventions -- 12 Conclusion -- References -- High Density Lipoproteins: Is There a Comeback as a Therapeutic Target? -- 1 Introduction -- 2 Possible Reasons for HDL-Cś Clinical Futility -- 2.1 Lack of Causality -- 2.2 Epidemiology and Human Genetics Disprove ``the Higher the Better ́́Concept -- 2.3 Limitations of HDL Modifying Drugs -- 2.3.1 Neither Fibrates nor Nicotinic Acid Specifically Target HDL Metabolism -- 2.3.2 CETP Inhibitors Block Rather than Promote Reverse Cholesterol Transport -- 2.3.3 Combination with High-Intensity Statins: The Winner Takes it All -- 2.4 Wrong Biomarker ``the Good Cholesterol ́́-- 3 Consequences and Perspectives -- 3.1 The Search for Novel HDL-Biomarkers -- 3.2 Ongoing and Novel Drug Developments -- 3.2.1 Reconstituted HDL, apoA-I Mimetic Peptides, and Recombinant LCAT -- 3.2.2 Apabetalone -- 3.2.3 PPAR Modulators -- 3.2.4 ANGPTL3 and Endothelial Lipase -- 3.2.5 ApoC-III Inhibition -- 3.2.6 HDL-C Lowering Therapies: Probucol and Androgens -- 3.3 Other Disease Targets -- 3.3.1 Diabetes -- 3.3.2 Chronic Kidney Disease -- 3.3.3 Infections -- 3.3.4 Autoimmune Diseases -- 3.3.5 Cancer -- 3.3.6 Behind the Blood Brain Barrier: Alzheimerś Disease and Age Related Macular Degeneration -- 3.4 Implications for Nowadayś Clinical Practice -- References -- Lipoprotein(a) -- 1 Introduction -- 2 Sites of Production and Catabolism of Lp(a) -- 3 Physiology and Pathophysiology of Lp(a) -- 4 Genetic Control of Lp(a) Concentrations -- 5 Lp(a) Concentrations and Risk for CVD -- 5.1 Searching for Lp(a) Thresholds Associated with an Increased Coronary Artery Disease Risk.
|
| 505 |
8 |
|
|a 5.2 Lp(a) and Other Vascular Diseases -- 5.3 Differences Between Primary and Secondary Prevention Studies -- 5.4 Is Lp(a) an Independent Risk Factor for CVD? -- 6 What Evidence Do We Have for a Causal Association of High Lp(a) with CVD? -- 7 RNA-Targeting Therapies to Specifically Lower Lp(a) -- 7.1 Antisense Oligonucleotides (ASO) Against Apolipoprotein(a) -- 7.2 Short Interfering RNA (siRNA) to Target Apo(a) -- 8 Other Lipid-Lowering Drugs and Therapies with Possible Influence on Lp(a) Concentrations and Clinical Outcomes -- 8.1 Lipoprotein Apheresis -- 8.2 PCSK9 Inhibitors -- 8.3 Statins -- 8.4 Drugs That Are Probably No Longer Followed for Lp(a)-Lowering Potential -- 9 Therapeutic Lowering of Lipoprotein(a): How Much Is Enough? -- 10 Conclusions -- References -- Nonalcoholic Fatty Liver Disease -- 1 Epidemiology -- 1.1 Definition, Prevalence, and Incidence of NAFLD -- 1.2 Association with Other Diseases -- 1.3 Clinical, Economic, and Social Burden of NAFLD -- 2 Pathophysiology of NAFLD -- 2.1 Intrahepatic Disturbances During NAFLD -- 2.1.1 Lipo- and Glucotoxicity -- 2.1.2 Oxidative Stress and Mitochondrial Dysfunction -- 2.1.3 Hepatic Inflammation and Fibrosis -- 2.2 Metabolic Crosstalk in NAFLD -- 2.3 Genetic Predisposition to NAFLD -- 3 Therapeutics -- 3.1 Dietary/Lifestyle Intervention and Bariatric Surgery -- 3.2 Targeting Lipotoxicity -- 3.3 Targeting Insulin/Glucose Metabolism -- 3.4 Targeting Hepatic Inflammation and Fibrosis -- 3.5 Targeting Bile Acid Metabolism -- 4 Conclusion -- References -- Prevention and Treatment of Atherosclerosis: The Use of Nutraceuticals and Functional Foods -- 1 Introduction -- 2 Red Yeast Rice -- 2.1 Untoward Effects -- 3 Phytosterols and Phytostanols -- 3.1 Untoward Effects -- 4 Berberine -- 4.1 Untoward Effects -- 5 Fiber -- 5.1 Untoward Effects -- 6 Supplements in the Pipeline -- 6.1 Astaxanthin.
|
| 505 |
8 |
|
|a 6.2 Hydroxytyrosol -- 6.3 Probiotics -- 6.4 Bergamot -- 7 Conclusions -- References -- Part III: Hypothesis Based Approaches to Unravel Novel Targets -- Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis -- 1 Introduction -- 2 Types of Adipose Tissue and Their Impact on Cardiovascular Disease -- 2.1 White Adipose Tissue -- 2.2 Thermogenic Adipose Tissue -- 2.3 Perivascular Adipose Tissue -- 3 Therapies Targeting Adipose Tissue with Proven Clinical Efficacy in the Treatment of Atherosclerosis -- 3.1 Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Agonists -- 3.2 Niacin -- 3.3 Renin-Angiotensin System Blockade -- 4 Novel Therapeutic Targets in Adipose Tissue for Treatment of Atherosclerosis -- 4.1 Promoting Lipoprotein Disposal and Lipid Storage in Adipose Tissues -- 4.2 Boosting Thermogenic Activation -- 4.3 Targeting Inflammation in Adipose Tissue -- 4.4 Hormones Derived from Thermogenic Adipose Tissue -- 4.5 De Novo Lipogenesis-Derived Lipokines -- 5 Future Directions -- References -- Microbiome and Cardiovascular Disease -- 1 Introduction -- 2 Gut and Oral Microbiome Communities: Potential Drivers of ASCVD? -- 2.1 Other Microbiome Community Members -- 2.1.1 Viruses and Bacteriophages -- 3 Microbiome-Derived Metabolites -- 3.1 TMAO -- 3.2 Imidazole-Propionate -- 3.3 Short-Chain Fatty Acids -- 3.4 Other Microbiome-Produced Metabolites Associated with ASCVD -- 4 Bile Acids -- 4.1 Bile Acid Metabolism -- 4.2 Regulation by Bile Acids -- 5 Summary and Future Perspectives -- References -- Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis -- 1 Introduction -- 2 Smooth Muscle Cell Phenotype Switch and Extracellular Matrix Production -- 3 Extracellular Matrix (ECM) -- 3.1 Fibrillar Matrix -- 3.2 Proteoglycans: Non-fibrillar Components of the ECM -- 3.2.1 Versican -- 3.2.2 Biglycan -- 3.2.3 Decorin.
|
| 505 |
8 |
|
|a 3.2.4 Perlecan.
|
| 588 |
|
|
|a Description based on publisher supplied metadata and other sources.
|
| 590 |
|
|
|a Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2023. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Binder, Christoph J.
|
| 776 |
0 |
8 |
|i Print version:
|a von Eckardstein, Arnold
|t Prevention and Treatment of Atherosclerosis
|d Cham : Springer International Publishing AG,c2022
|z 9783030860752
|
| 797 |
2 |
|
|a ProQuest (Firm)
|
| 830 |
|
0 |
|a Handbook of Experimental Pharmacology Series
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/matrademy/detail.action?docID=6877842
|z Click to View
|
